Signature Discoveries

BME faculty member James McElhaney describes the mechanical properties of cranial bone. He goes on to describe many measurements and models of head, neck and spinal cord injury mechanisms that have widely informed the design of protective football and motorcycle helmets, restraint systems, airbags and swimming pools.

Fredrick “Fritz” Thurstone, one of the founders of Duke’s biomedical engineering department, and graduate student Olaf von Ramm lay the foundation for the phased-array imaging system that revolutionizes cardiac imaging and paves the way for real-time ultrasound imaging in clinical practice.

Henry Petroski (CEE) publishes To Engineer Is Human: The Role of Failure in Successful Design, the first of nearly 20 popular and critically acclaimed books that make his reputation as “America’s poet laureate of technology.”

Olaf von Ramm and Stephen Smith (BME) invent the first real-time 3-D ultrasonic scanner (4-D). It is now used worldwide in multiple medical specialties.

Earl Dowell, Kenneth Hall and MEMS team demonstrate an innovative method of modeling complex, time-varying fluid flows much more efficiently and compactly than previous methods, opening up new possibilities for understanding and controlling such flows. Their insights are widely used in current airframe and turbine designs for power plants, airplanes and windmills. Most recently these ideas have been extended to modeling turbulence in fluids, which some say is the great unsolved problem in classical mechanics.

Ray Ideker with Patrick Wolf and William Smith (BME) optimize biphasic waveforms for defibrillation of the heart. This discovery improved clinical defibrillators and made possible smaller and lighter implantable devices using transvenous lead systems.

Duke engineering distinguished alumnus and adjunct professor Blake Wilson develops the continuous interleaved sampling (CIS) processing strategy for cochlear implants, dramatically improving how implanted patients perceive speech. The breakthrough became the basis for current sound-processing strategies that launched a rapid expansion in the use of cochlear implants. In 2013 Wilson received the Lasker Award (“American Nobel”) in recognition of the work.

BME’s Howard Clark and Duke cardiologist Richard Stack patent the first bioabsorbable stent, which inspired modern stents with bioabsorbable sheaths that deliver drugs inside diseased vessel walls and then biodegrades, eliminating many complications associated with permanent stents.

David Needham (MEMS), working with radiation oncologist Mark Dewhirst, invents a new cancer treatment using heat-sensitive liposomes to precisely deliver high concentrations of cancer drugs within tumors, while sparing normal tissue. The therapy is currently in clinical trials.

Adrian Bejan (MEMS) postulates the constructal law of design and evolution in nature, which states that movement (or “flow”) systems such as trees, rivers or air currents evolve into configurations that provide easier and easier access to flows. Now internationally recognized, the law is increasingly finding applications in improving design and maximizing efficiency of manmade systems. In 2001 Bejan was ranked among the 100 most highly cited authors worldwide in engineering by the Institute for Scientific Information.

Duke anesthesiologist and biomedical engineer Laura Niklason creates a novel “bioreactor” system and uses it to grow blood vessels that look and act like the real thing. A significant advance in the field of tissue engineering, the discovery ultimately leads to the first U.S. implantation of a bioengineered blood vessel, performed at Duke University Medical Center in 2013.

Ashutosh Chilkoti (BME) develops the first elastin-like polypeptide fusion that provides a new method to purify proteins without chromatography—opening a new path to developing drugs with greater potency and fewer side effects. The innovation launches a new avenue for drug delivery that is currently in development by research groups worldwide, and launches the startup company PhaseBio pharmaceuticals, where the technology is in late-stage clinical trials for drugs to treat endocrine and metabolic disorders and heart disease.

Farshid Guilak (BME) develops new methods to isolate stem cells from human fat and use them to regenerate articular cartilage and other musculoskeletal tissues. Lauded as a breakthrough in tissue engineering, and providing an alternative to embryonic stem cells for use in research and treatments, the technology is currently in pre-clinical trials.

Joseph Izatt‘s BME research group demonstrates more than 100-fold improvement in the sensitivity of Optical Coherence Tomography (OCT) biomedical imaging technology, which he helped develop for imaging delicate structures of the eye while at MIT. The more sensitive Fourier Domain OCT technology is now the standard of care worldwide for diagnosis and treatment monitoring of blinding retinal diseases, with millions of patients imaged with this technology every year.

Gregg Trahey and Kathryn Nightingale (BME) demonstrate a device that uses ultrasound to image and measure stiffness of breast tissue and, eventually, other tissues. The advance allows clinicians to detect and diagnose ailments such as liver scarring and prostate cancer without having to make a single incision in the patient.

Lawrence Carin, Leslie Collins and other Duke electrical and computer engineering researchers develop new data-processing techniques for detecting hidden landmines and other explosive devices. The techniques are now in use by the U.S. military.

Miguel Nicolelis, Craig Henriquez and team members at the Duke Center for Neuroengineering demonstrate that a monkey can control a robotic arm using thought alone, a major breakthrough in the field of brain-machine interfaces. In 2014, Nicolelis created a brain-machine exoskeleton that enabled a paraplegic youth to deliver the opening kick in soccer’s World Cup.

David Smith (ECE) and Sir John Pendry of Imperial College, London, introduce the concept of “transformation optics” as a means of designing invisibility cloaks and other exotic optical structures. Later that year, David Smith, Steve Cummer and their teams at Duke demonstrate the first working “invisibility cloak,” using metamaterials to render objects undetectable at microwave frequencies.

With support from the Duke-Coulter Translational Partnership, BME’s Nimmi Ramanujam brings to market a novel instrument that uses light waves to detect cancer and assess treatment effectiveness in real time. The non-invasive device is currently in use at several U.S. academic medical centers and is being adapted for use in resource-limited settings.

Lingchong You and BME colleagues engineer a synthetic predator-prey ecosystem using gene circuits. It is considered one of the most influential studies in the new field of synthetic biology.

2010

Mark Wiesner and researchers in CEINT demonstrate that nanomaterials accumulate in living organisms and can become more concentrated the further up the food chain they go, revealing the potential impacts nanotechnology could have on the environment.

Pratt students working with BME’s Bob Malkin invent the Pratt Pouch, a ketchup-packet-like device to improve storage and delivery of medication to prevent HIV transmission in low-resource areas. The device, named one of the World Health Organization’s Top 10 most Innovative Health Technologies for 2012, is now in clinical trials in Zambia and Ecuador.

David Brady (ECE) leads development of the world’s first gigapixel camera, which can capture images with unprecedented detail. The scalable array technology opens the door for vastly increased resolution and field of view in consumer electronics, broadcast media and security cameras.

Steven Cummer (ECE) and his team demonstrate the first three-dimensional acoustic cloaking device, which uses metamaterials to reroute sound waves.

Nenad Bursac (BME) creates the first lab-grown muscle that can heal itself after implantation into a living animal. The advance is an important step toward growing viable muscle for studying diseases and treating injuries.

Charles Gersbach (BME) becomes the first scientist to use CRISPR to successfully treat a genetic disorder—Duchenne muscular dystrophy—in a fully developed living animal with a strategy that has the potential to be translated to human therapy.